spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

SICK Goes Flat Out for Performance with Mini Smart Sensors

SICK



SICK has launched the versatile W4F family of miniature smart sensors, developed to achieve next-generation detection performance and incorporating powerful new optical technologies, each purpose-designed to master common sensing challenges in pharmaceuticals with complete reliability.



The SICK W4F family of photoelectric smart sensors packs a choice of class-leading detection technologies and application-specific optics into the same, rugged, 16mm x 40mm x 12mm housing. Each features SICK’s trademark BluePilot push-turn pinpoint alignment and on-sensor status display. Impressing with their resilience to bright ambient light, the versatile W4F smart sensors multiply intelligent machine integration options for almost any application, no matter how tight the available mounting space.

“The SICK W4F is really a team of tiny superstar performers, and each is destined to be a future workhorse of the SICK smart sensor range,” explains David Hannaby, SICK’s UK Product Manager for Presence Detection.

“Superstar Performers”

“Whether you need to detect high-gloss, perforated, transparent, wire-thin or flat products, the W4F has a specialist Optical Expert up to the task. At the same time, the W4F’s extended smart sensor features unlock more diagnostics and monitoring, while process information including distance measurement can be output to configure smart automation tasks.



 “We have had excellent feedback from the first users of the SICK W4F photoelectric sensors. They have told us that they are getting the best-ever ambient light and sunlight suppression performance, as well as maximum immunity to all sources of optical interference.”

The SICK W4F family comprises eight different sensor types, split into the Optical Experts together with a range known as Optical Standards, but which deliver performance significantly above the market standard.

Optical Experts

Among the W4F Optical Experts is the new SICK W4F MultiSwitch with two separate switching points, together with a distance measurement output in mm. It is therefore possible e.g. to reliably detect an object both when it is upright or lying on its side using just one sensor, or to enable a robot arm to travel more quickly by allowing it to stop in two steps. Using distance measurement, an automated response can be designed to alert when products drift away from a pre-set detection position on a conveyor, or to measure the width of a roll of paper.

Another highlight is the new foreground suppression sensor optic, capable of reliably detecting low, flat objects less than one 1mm in depth on a conveyor. The new W4F ForegroundSuppression sensor excels when detecting flat products and blister packs, even if they are extremely dark and glossy.

The SICK W4F V-Optic features a new V-focused light beam, designed to achieve exceptional accuracy when detecting mirror-reflective or completely transparent products such as plastic films. Low-remission, or tiny objects are detected reliably, as well as objects as thin as a single fuse wire.

The SICK W4F DoubleLine upgrades SICK’s MultiLine technology adding more power and performance to detect components that have uneven surfaces, recesses, holes, perforations, grids or grooves, ideal for packs of pharmaceuticals.

Even when faced with dirt, vibrations or high temperature, the W4F is designed to self-monitor and will continue to deliver precise results even under tough conditions thanks to its rugged IP66/IP67 VISTAL® housing and highly-reliable optics.

Optical Standards

The W4F Optical Standards sensors have already proven themselves in the field as space-saving and high-performing all-rounders. The through-beam photoelectric sensor has a long sensing range of up to 8 metres, while the photoelectric retro-reflective sensor extends up to 5 metres. Together with two photoelectric proximity sensors with background suppression, the Optical Standards achieve exceptionally reliable object detection. The W4F Narrow-beam sensor uses a highly-concentrated light beam and point geometry to detect jet black objects with a remission of less than one percent.

Using SICK’s intuitive BluePilot, precise alignment is easy using the push-turn mechanism guided by the on-sensor LED display. BluePilot also provides a visual indication of detection quality and enables any loss of detection capability, e.g. as a result of dirt on the lens, to be corrected before causing unplanned downtime.

Useful IO-Link features include a ‘current receiver level’ read-out enabling detection to be monitored in real time. Extensive diagnostic functions ensure the system can monitor sensor status and can respond if process parameters such as temperature or degree of contamination deviate beyond pre-set limits. Extensive diagnostic data also enables rapid identification of the cause of failure, e.g. at critical temperatures, the W4F can automatically initiate maintenance, thus preventing failures.
phone 07928 809035
email sharon@sharonlindsaypr.co.uk
web https://www.sick.com/us/en/
email Waldkirch House, 39 Hedley Road, St Albans, Hertfordshire, AL1 5BN
 
Print this page
Send to a friend
   
spacer
News and Press Releases

bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.

Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.
More info >>


White Papers

Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies

PCI Pharma Services

Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >>

Industry Events

MedTech Integrates 2021

22 June 2021, VIRTUAL CONFERENCE

Inspired by the success of the inaugural MedTech Integrates in last October, Life Science Integrates is delighted to announce the second Medtech Integrates conference. This one-day gathering of technology, diagnostics, devices and therapeutics organisations, as well as clinicians and regulators, provides a platform to discuss the major challenges impacting the MedTech sector.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement